- Patent Title: Fusion peptides of CD4 helper T cell epitopes and vaccines thereof
-
Application No.: US16650318Application Date: 2018-09-28
-
Publication No.: US11352411B2Publication Date: 2022-06-07
- Inventor: Jianqing Xu , Yang Huang , Xiaoyan Zhang
- Applicant: VACDIAGN BIOTECHNOLOGY CO., LTD
- Applicant Address: CN Suzhou
- Assignee: VACDIAGN BIOTECHNOLOGY CO., LTD
- Current Assignee: VACDIAGN BIOTECHNOLOGY CO., LTD
- Current Assignee Address: CN Suzhou
- Agency: Christensen O'Connor Johnson Kindness PLLC
- Priority: WOPCT/CN2017/104401 20170929
- International Application: PCT/CN2018/108331 WO 20180928
- International Announcement: WO2019/062853 WO 20190404
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K38/00 ; C07K14/005 ; C07K14/16 ; C07K14/02 ; C07K14/73 ; A61P31/22 ; A61P35/00 ; A61K39/12

Abstract:
Disclosed are a fusion peptide of CD4 helper T cell epitopes, a nucleic acid encoding the same and an immunogenic composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope and an influenza virus epitope. The epitope fusion peptide can substantially improve the level of cellular immune response to a target immunogen, particularly a weak immunogen, and is an effective means for overcoming the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen, and is suitable for efficiently enhancing the efficacy of vaccine.
Public/Granted literature
- US20200216516A1 FUSION PEPTIDES OF CD4 HELPER T CELL EPITOPES AND VACCINES THEREOF Public/Granted day:2020-07-09
Information query